Baystreet.ca RSS Feed http://www.baystreet.ca/rss/MasterRSS.aspx en-us Copyright (c) 2024 Baystreet.ca Inc. All rights reserved. 11/15/2024 7:19:15 PM <![CDATA[Element Fleet Management Corp "HOLD"]]>Fri, 15 Nov 2024 11:59:00 ESThttps://www.baystreet.ca/articles/analyst_ratings.aspx?105435<![CDATA[Gold Set for Worst Week in 3 Years]]>Fri, 15 Nov 2024 07:29:00 ESThttps://www.baystreet.ca/articles/commodities.aspx?id=7582Friday, November 15, 2024


Gold Set for Worst Week in 3 Years


Prices for gold were little changed on Friday, but was set for its worst week in more than three years, hurt by a stronger U.S. dollar amid expectations of fewer Federal Reserve rate cuts.

Spot gold rose 0.1% to $2,569.69 per ounce after a five-session slide. It was down more than 4% for the week so far.

Bullion hit a two-month low in the previous session and has declined more than $220 from the record peak hit last month.

U.S. gold futures were up 0.1% at $2,574.50.

According to the CME Fedwatch tool, markets see a 59% chance of a 25-basis-point rate cut in December, down from 83% a day ago.

With a quiet U.S. calendar next week, experts say, gold could rebound, potentially retesting $2,600 level.

Spot silver rose 0.2% to $30.52 U.S. per ounce, platinum edged up 0.1% to $940.68 and palladium added 0.5% to $946.00. All three metals were headed for weekly falls.

]]>
<![CDATA[Alibaba Skids on Latest Quarterly Figures ]]>Fri, 15 Nov 2024 10:20:00 ESThttps://www.baystreet.ca/articles/techinsider.aspx?id=4713Friday, November 15, 2024

Alibaba Skids on Latest Quarterly Figures


Chinese e-commerce behemoth Alibaba (NYSE:BABA) on Friday beat profit expectations in its September quarter, but sales fell short as sluggishness in the world’s second-largest economy hit consumer spending.

Alibaba said net income rose 58% year-on-year to 43.9 billion Chinese yuan ($6.07 billion) in the company’s quarter ending Sept. 30, on the back of the performance of its equity investments. This compares to an LSEG forecast of 25.83 billion yuan.

“The year-over-year increases were primarily attributable to the mark-to-market changes from our equity investments, decrease in impairment of our investments and increase in income from operations,” the company said of the annual profit jump in its earnings statement.

Revenue, meanwhile, came in at 236.5 billion yuan, 5% higher year-on-year but below an analyst forecast of 238.9 billion yuan, according to LSEG data.

The company’s New York-listed shares have gained ground this year to date, up almost 17%. The stock was 3% higher in premarket trading at 12:24 p.m. London time, after the release of the quarterly earnings. They opened in New York down $1.74, or 1.9%, to $88.80.

Investors are closely watching the performance of Alibaba’s main business units, Taobao and Tmall Group, which reported a 1% annual uptick in revenue to 98.99 billion yuan in the September quarter.

]]>
<![CDATA[Economic Calendar]]>Fri, 15 Nov 2024 07:19:15 ESThttps://www.baystreet.ca/articles/econ_calendar.aspx?id=18125November 2024
 

DATE

STATISTIC FOR CURRENT MONTH PREVIOUS MONTH
Friday, November 1, 2024 Markit Canada Manufacturing PMI 9:30 a.m. Oct Manufacturing PMI in Canada increased to 51.10 points in October from 50.40 points in September. Manufacturing PMI in Canada averaged 52.33 points from 2011 until 2024, reaching an all time high of 58.90 points in March of 2022 and a record low of 33 points in April of 2020. Registering 50.4, up from 49.5 in August, the seasonally-adjusted S&P Global Canada Manufacturing Purchasing Managers’ Index™ (PMI®) edged back above the critical 50.0 no-change mark in September to signal a first improvement in operating conditions since April 2023.
Tuesday, November 5, 2024 Canadian International Merchandise Trade: 8:30am Sept In September, Canada's merchandise exports decreased 0.1%, while imports fell 0.4%. Consequently, Canada's merchandise trade deficit with the world narrowed from $1.5 billion in August to $1.3 billion in September. In August, Canada's merchandise exports fell 1.0%, while imports edged up 0.3%. Consequently, Canada's merchandise trade balance with the world widened from a revised deficit of $287 million in July to a deficit of $1.1 billion in August.
Wednesday, November 6, 2024 IVEY Purchasing Managers Index: 10:00am Oct The index registered at 52 in October, down from the 53.1 figure in September. and was below the 53.4 number for October 2023. The index registered at 53.1 in September, much higher than the 48.1 figure the month before and identical to the 53.1 reading in September 2023.
Friday, November 8, 2024 Labour Force Survey: 8:30am Oct Employment was little changed in October (+15,000; +0.1%) and the employment rate fell 0.1 percentage points to 60.6%. The unemployment rate was unchanged at 6.5%. Employment rose by 47,000 (+0.2%) in September while the employment rate declined 0.1 percentage points to 60.7%. The unemployment rate fell 0.1 percentage points to 6.5%.
Tuesday, November 12, 2024 Building Permits: 8:30am Sept The total value of building permits in Canada increased by $1.3 billion (+11.5%) to $13.0 billion in September. The total value of building permits in Canada decreased by $858.1 million (-7.0%) to $11.5 billion in August.
Friday, November 15, 2024 CREAstats - MLS Sales: 8:30am Oct Home sales activity recorded over Canadian MLS® Systems increased 7.7% on a month-over-month basis in October 2024, reaching its highest level since April 2022. Home sales recorded over Canadian MLS® Systems climbed 1.9% on a month-over-month basis in September 2024, reaching their highest level since July 2023
Friday, November 15, 2024 Wholesale Trade: 8:30am Sept Wholesale sales (excluding petroleum, petroleum products, and other hydrocarbons and excluding oilseed and grain) rose 0.8% to $82.3 billion in September. Wholesale sales fell 0.6% to $81.9 billion in August.
Friday, November 15, 2024 New Motor Vehicle Sales: 7:30am Sept New motor vehicle sales totaled 168,500 in September, slightly better than August's 166,000 Motor vehicle sales registered 166,000 in August, from 169,000 in the prior-year month.
Friday, November 15, 2024 Monthly Survey of Manufacturing: 8:30am Sept Manufacturing sales declined 0.5% in September, mainly on lower sales of petroleum and coal products as well as lower production of aerospace products and parts. Total manufacturing sales declined 1.3% in August, largely on lower sales of primary metals as well as petroleum and coal products. The declines were partially offset by higher production of aerospace products and parts.
Monday, November 18, 2024 Housing Starts: 8:15am Oct --- Canada Mortgage and Housing Corporation said the seasonally-adjusted annualized rate of housing starts rose to 223,808 units from a revised 213,012 units in August.
Monday, November 18, 2024 Canada's International Transactions in Securities: 8:30am Sept --- Canadian investors increased their exposure to foreign securities by $12.3 billion in August, mainly in US shares. Meanwhile, foreign investors acquired $10.0 billion of Canadian securities.
Tuesday, November 19, 2024 Consumer Price Index: 8:30am Oct --- CPI rose 1.6% on a year-over-year basis in September, down from a 2.0% increase in August. On a seasonally adjusted monthly basis, the CPI was unchanged at 0.0% in September.
Thursday, November 21, 2024 New Housing Price Index: 8:30am Oct --- The national index remained unchanged for the second consecutive month in September.
Thursday, November 21, 2024 Industrial Product Price Index: 8:30am Oct --- The Industrial Product Price Index fell 0.6% month over month in September and decreased 0.9% year over year.
Thursday, November 21, 2024 Raw Materials Price Index: 8:30am Oct --- The Raw Materials Price Index declined 3.1% month over month in September and fell 8.8% year over year.
Friday, November 22, 2024 Retail Trade: 8:30am Sept --- Retail sales increased 0.4% to $66.6 billion in August. Sales were up in four of nine subsectors and were led by increases at motor vehicle and parts dealers.
Thursday, November 28, 2024 Payroll Employment, Earnings and Hours: 8:30am Sept --- he number of employees receiving pay and benefits from their employer—measured as "payroll employment" in the Survey of Employment, Payrolls and Hours—was little changed in August (+13,500), following an increase of 39,500 (+0.2%) in July and a decline of 22,900 (-0.1%) in June. On a year-over-year basis, payroll employment was up 176,700 (+1.0%) in August.
Friday, November 29, 2024 GDP: 8:30am Sept --- Real gross domestic product was essentially unchanged in August as increases in services-producing industries were offset by declines in goods-producing industries.
Wednesday, December 11, 2024 BoC Interest Rate Decision: 10:00am Dec --- The Bank of Canada cut its benchmark interest rate by 50 basis points on Wednesday, the fourth consecutive decrease since June, bringing its policy rate to 3.75%
]]>
<![CDATA[Canada Post Workers Launch Strike, Disrupting Holiday Shipments ]]>Fri, 15 Nov 2024 10:01:00 ESThttps://www.baystreet.ca/articles/economiccommentary.aspx?id=4154Canada Post Workers Launch Strike, Disrupting Holiday Shipments


About 55,000 postal workers across Canada are on strike, disrupting mail and parcel deliveries leading into the busy year-end holidays.

The Canadian Union of Postal Workers (CUPW) launched the strike at midnight on Nov. 15 after failing to reach a new collective agreement with their employer, Canada Post.

The strike comes ahead of Black Friday and the start of the holiday shopping season, when Canadians rely on the postal system to send and receive gifts, packages, and Christmas cards.

Canada Post said in a written statement that its operations have been shutdown, impacting millions of Canadian homes and businesses.

The Crown corporation said no mail or parcels will be processed or delivered during the strike, and some post offices will be closed.

Once operations resume, the corporation said that mail and parcels will be delivered on a first-come, first-serve basis.

Workers gave Canada Post a 72-hour strike notice on Nov. 12. In October, workers voted 95% in favour of a strike.

Canada Post's latest contract offer included wage increases that totaled 11.5% over four years. It also offered protection of the traditional defined benefit pension for current employees.

However, CUPW has said management’s latest offer wasn't enough and that the two parties remain far apart on several important issues.

Canada Post, which is a Crown Corporation, has lost a total of $3 billion since 2018 as fewer people and businesses use the postal system.


]]>
<![CDATA[Asia Directionless After Powell Speech]]>Fri, 15 Nov 2024 07:07:00 ESThttps://www.baystreet.ca/articles/foreignmarketwrap.aspx?id=4556Friday, November 15, 2024

Asia Directionless After Powell Speech


Asia markets were mixed Friday as Wall Street fell after U.S. Federal Reserve Chair Jerome Powell indicated the central bank was in no rush to cut rates, with investors also assessing China and Japan economic data.

In Japan, the Nikkei 225 index regained 107.21 points, or 0.3%, to 38,642.91.

Separately, Japan on Friday reported its third-quarter GDP expanded 0.3% year on year, snapping two straight quarters of year-on-year declines. On a quarter-on-quarter basis, GDP rose 0.2%, in line with Reuters poll estimates.

In Hong Kong, the Hang Seng Index ditched 9.47 points, or 0.1%, to 19,426.34.

Speaking in Dallas, Powell pointed out that strong U.S. economic growth will allow policymakers to take their time in deciding how far and how fast they should lower interest rates.

CHINA

In Shanghai, the CSI 300 dumped 70.79 points, or 1.8%, to 3,968.83.

In Asia, investors assessed key economic data from China on Friday, which included October numbers for retail sales, industrial production and urban unemployment.

China’s retail sales rose more than expected in October, while industrial production and investment data missed forecasts.

The unemployment rate in cities fell to 5% in October, down from 5.1% in September.

In other markets

In Taiwan, the Taiex changed direction and gained 27.39 points, or 0.1%, to 22,742.77.

In Korea, the Kospi index fell two points, or 0.1%, to 2,416.86.

In Singapore, the Straits Times Index inched up 6.54 points, or 0.2%, at 3,744.70.

In New Zealand, the NZX 50 dropped 8.06 points, or 0.1%, to 12,684.88.

In Australia, the ASX 200 gathered 61.2 points, or 0.7%, to 8,285.15.

]]>
<![CDATA[Fed Chair Jerome Powell Says There’s No Hurry To Cut Interest Rates ]]>Fri, 15 Nov 2024 09:53:00 ESThttps://www.baystreet.ca/articles/globalmarkets.aspx?id=3603Federal Reserve Chair Jerome Powell has said that a strong U.S. economy will allow the central bank to take its time lowering interest rates.

Speaking to business leaders in Dallas, Texas, Powell said: “The economy is not sending any signals that we need to be in a hurry to lower rates.”

The Fed Chair added that the U.S. labour market is holding up well despite disappointing job growth in October that he attributed to storm damage and labour strikes.

Powell noted that the U.S. unemployment rate has been rising but has flattened out in recent months and remains low by historic measures.

On the question of inflation, he said progress has been “broad based,” noting that the central bank expects it to continue falling back towards its 2% target.

Powell highlighted that inflation is currently at 2.3%, or 2.8% excluding volatile food and energy prices.

“We are committed to finishing the job” on inflation, said Powell.

Powell’s cautious view has led future traders to lower their expectations for an interest rate cut this December. Traders are now placing odds of a year-end rate cut at 50%.

The remarks come a week after the Federal Reserve lowered the central bank’s benchmark interest rate by 25-basis points, taking it down to a range of 4.50% to 4.75%.

So far in 2024, the Fed has lowered interest rates a total of 75-basis points. Markets still expect the Fed to continue cutting rates in 2025.


]]>
<![CDATA[TSXV New Listings]]>Thu, 04 Jan 2024 06:16:00 ESThttps://www.baystreet.ca/articles/ipo_tsx.aspx?id=10023 Company Name Ticker Date Mawson Gold Limited MAW 04-01-2024 Artrari One Capital Corp. AOCC.P 05-01-2024 Euromax Resources Ltd. EOX 09-01-2024 Oa Capital Corp. OACP 09-01-2024 Power One Resources Corp. PWRD 18-01-2024 Zodiac Gold Inc. ZAU 29-01-2024 Amaya Big Sky Capital Corp. AMYA.P 30-01-2024 Coco Pool Corp. CCPC.P 08-02-2024 Goldgroup Mining Inc. GGA 20-02-2024 Navion Capital II Inc. NVN.P 29-02-2024 Atha Energy Corp. SASK 04-03-2024 Sitka Gold Corp. SIG 05-03-2024 Kubera Gold Corp. KBRA 13-03-2024 Coniagas Battery Metals Inc. cOS 18-03-2024 Valleyview Resources Ltd. VVR 28-03-2024 Tokens.com Corp. COIN 28-03-2024 Hypercharge Networks Corp. HC 28-03-2024 Oracle Commodity Holding Corp. ORCL 05-04-2024 Kootenay Resources Inc. KTRI 01-05-2024 OnGold Resources Ltd. ONAU 08-05-2024 Chicane Capital II Corp. CHII.P 27-05-2024 Mogotes Metals Inc. MOG 12-06-2024 Nations Royalty Corp. NRC 21-06-2024 AuMega Metals Ltd AUM 26-06-2024 AC/DC Battery Metals Inc. ACDC 27-06-2024 Chablis Capital Corp. CCZ.P 28-06-2024 Treasury Metals Inc. TML 05-07-2024 Florida Canyon Gold Inc. FCGV 16-07-2024 Rua Gold Inc. RUA 29-07-2024 Borealis Mining Company Limited BOGO 07-08-2024 Culico Metals Inc. CLCO 16-08-2024 High Arctic Overseas Holdings Corp. HOH 16-08-2024 Mawson Finland LImited MFL 19-08-2024 Vizsla Royalties Corp. VROY 26-08-2024 Greenheart Gold Inc. GHRT 06-09-2024 Fiddlehead Resources Corp. FHR 10-09-2024 BIGG Digital Assets Inc. BIGG 17-09-2024 Saga Metals Corp. SAGA 23-09-2024 Mithril Silver and Gold Limited MSG 27-09-2024 International Battery Metals Ltd. IBAT 07-10-2024 Conavi Medical Corp. CNVI 16-10-2024 Metavista3D Inc. DDD 28-10-2024 CanCambria Energy Corp. CCEC 29-10-2024 Silver47 Exploration Corp. AGA 14-11-2024]]><![CDATA[Profit-Taking Marks Friday ]]>Fri, 15 Nov 2024 04:49:00 ESThttps://www.baystreet.ca/articles/marketupdates.aspx?id=13642Friday, November 15, 2024

16:49 PM EST
Profit-Taking Marks Friday

Tilray, Advantage Featured




Canada's main stock index posted broad-based declines on Friday as the prospect of a slower pace of Federal Reserve interest rate cuts spurred investors to take some profits on gains made since the U.S. presidential election.

The TSX was in the minus column 158.99 points to close Friday at 24,890.68. On the week, though, the index gained 131 points, or 0.5%.

The Canadian dollar dipped 0.14 cents to 70.98 cents U.S.

In corporate news, space company MDA Space reported its third-quarter results and forecast annual revenue above estimates. MDA shares shed 88 cents, or 3.4%, to $24.97.

Health-care stocks took a pounding, as Tilray lost seven cents, or 3.6%, to $1.90, while Bausch Health Companies staggered 35 cents, or 2.8%, to $11.98.

Energy stocks fell as well, as Advantage Oil slipped 44 cents, or 4.9%, to $8.61, while Canadian Natural Resources gave up $1.24, or 2.6%, to $46.61.

One bright spot was a modest gain for the shares of BCE… seven cents to $37.81, BCE pays a dividend in excess of 10%, but the shares have been in a downward spiral since the company's announcement of a U.S. acquisition earlier this month.

In matters economic, Statistics Canada said manufacturing sales declined 0.5% in September, mainly on lower sales of petroleum and coal products as well as lower production of aerospace products and parts. Wholesale sales (excluding petroleum, petroleum products, and other hydrocarbons and excluding oilseed and grain) rose 0.8% to $82.3 billion in September.

New motor vehicle sales totaled 168,500 in September, slightly better than August's 166,000.

The Canadian Real Estate Association said MLS listings increased 7.7% on a month-over-month basis in October, reaching its highest level since April 2022.

ON BAYSTREET

The TSX Venture Exchange picked up 0.71 points on the day to 591.22, for a loss on the week of 12.7 points, or 2.1%.

All but two 12 subgroups lost ground, weighed most by health-care, down 1.3%, energy, off 1.1%, and industrials, sliding 0.9%

Only utilities, picking up 0.1%, and consumer discretionary stocks, ahead 0.1%, resisted the negative tide.

ON WALLSTREET

Stocks tumbled on Friday as the post-election rally fizzled and investors fretted over the path of interest rates.

The Dow Jones Industrials fell 305.87 points to 43,444.99.

The S&P 500 dived 78.55 points, or 1.3%, to 5,870.62.

The NASDAQ Composite staggered 427.53 points, or 2.2%, to 18,680.13.

The S&P 500 posted a weekly loss of 2.1%, while the NASDAQ Composite slid about 3.2%. The 30-stock Dow fell 1.2% in the period.

Declines in pharmaceutical stocks weighed on the Dow and the S&P 500, with Amgen down about 4.2% and Moderna off by 7.3%.

President-elect Donald Trump said on Thursday that he planned to nominate vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.

October retail sales data on Friday showed a 0.4% increase, slightly better than the 0.3% forecast from economists polled by Dow Jones. That finding follows an October consumer inflation report that was in line with economists’ projections.

Prices for the 10-year Treasury regained strength, lowering yields to 4.44% from Thursday’s 4.45%. Treasury prices and yields move in opposite directions.

Oil prices sagged $1.66 to $67.04 U.S. a barrel.

Prices for gold eased $5.90 an ounce to $2,567,99 U.S.





]]>
<![CDATA[Stocks in Play: Enterprise Group, Inc.]]>Fri, 15 Nov 2024 10:21:37 ESThttps://www.baystreet.ca/articles/stocksinplay.aspx?id=43334Friday, November 15, 2024

10:21 AM EST - Enterprise Group, Inc. : Announced its upcoming investor presentation via webcast. Scheduled for Thursday, November 21st, 2024, at 2:00 p.m. ET/11:00 a.m. PT, the presentation will feature Enterprise Group's Chairman and CEO, Leonard Jaroszuk, President and Director Desmond O'Kell, and CFO Warren Cabral. They will review key aspects of the company's operations and provide insights into the recently disclosed third-quarter results. Enterprise Group, Inc. (T.E) shares were down $0.01 at 1.75.

]]>
<![CDATA[Armlogi Falls on Q1 Numbers ]]>Fri, 15 Nov 2024 10:13:00 ESThttps://www.baystreet.ca/articles/stockstowatch.aspx?id=19536Friday, November 15, 2024

Armlogi Falls on Q1 Numbers


Armlogi Holding Corp. (NASDAQ: BTOC) shares went downhill Friday, a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, reported financial results for the first quarter ended September 30, 2024.

Total revenue increased by $1.2 million, or 3.0%, to $42.5 million during the three months ended September 30, 2024, compared to $41.2 million for the same period in 2023.

The company's transportation services segment reported revenue of $28.5 million, a decrease of 4.2% from $29.7 million for the same period in 2023. The decrease was driven by decreases in customer order volume.

Its warehousing services segment generated $14.0 million, a 23.8% increase from $11.3 million for the same period in 2023. This growth was driven by the additional warehouses acquired in the last fiscal quarter.

This segment comprises inventory management and storage offerings.

Revenue from other services decreased by $0.2 million, or 92%. This segment is primarily comprised of customs brokerage services.

Costs of sales were $46.1 million during the three months ended September 30, 2024, an increase of $10.1 million or 28.0%, compared with $36.0 million for the same period in 2023.

BTOC shares fell 25 cents, or 4.6%, to $5.14.

]]>
<![CDATA[USD / CAD - Canadian dollar in dire straits]]>Fri, 15 Nov 2024 05:56:25 ESThttps://www.baystreet.ca/articles/forex_trader.aspx?id=105441- Powell supports cautious rate cut stance.

- US Retails Sales expected to slow.

- US dollar rally stalls.

USDCAD: open 1.4043, overnight range,1.4038-1.4072 close 1.4062, WTI $67.97, Gold, $2567.05

The Canadian dollar extended its losses again overnight, but it has managed to recover slightly in early NY trading. The bulk of the Canadian dollar losses can be attributed to incoming US President Donald Trump and his America First plans which include a 10% tariff bump across the board.

However, the Canadian dollar has problems of its own. The Financial Post reports that Canada’s record economic gap with the US is about to get wider. The article claims that Canada’s economy has been falling behind the United States and most major economies ever since the Trudeau government came to power.

The Canadian dollar’s more immediate problem is widening CAD/US interest rate differentials. The spread has widened to 115 bps in favour of the US and yesterday’s comments by Fed Chair Jerome Powell suggest they won’t narrow any time soon. Mr Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates.”

Traders are awaiting today’s US economic reports. US Retail Sales are expected to slow to 0.3% m/m form 0.4% m/m in September while Industrial Production and Capacity utilization data will be mixed. Canada releases Manufacturing and Wholesale Sales reports.

EURUSD stayed within a range of 1.0524-1.0581, reaching the upper end of the band during NY trading. The increase was partly attributed to profit-taking and unwinding of oversold positions, though the gains remained capped. Economic data from the euro area had little impact.

GBPUSD advanced from 1.2649 to 1.26697 despite disappointing economic data, including a modest 0.1% q/q rise in Q3 GDP versus the 0.2% forecast. Industrial and Manufacturing Production figures also fell short of expectations. Meanwhile, Bank of England Governor Andrew Bailey called for improved EU relations—perhaps hinting at "Brenter."

USDJPY declined from 156.75 to 155.22 before rebounding to 155.55 in NY. Japan's stronger-than-expected Q3 GDP (0.9% y/y vs. 0.7% forecast) drove the initial sell-off, which intensified after Finance Minister Kato’s verbal intervention prompted pre-weekend profit-taking.

AUDUSD edged up within a 0.6445-0.6480 range, supported by mixed Chinese economic data and a slight pullback in the US dollar.


















]]>
<![CDATA[Citigroup Vaults On Beating Quarterly Projections]]>Thu, 12 Oct 2017 10:07:02 ESThttp://www.baystreet.ca/articles.aspx?id=38460Earnings per Share came in for the quarter at $1.42, as opposed to $1.32 expected by experts. Revenue was $18.173 billion versus $17.896 billion expected. Fixed income trading: $2.877 billion versus a projected $2.84 billion

Said CEO Michael Corbat, "We had revenue increases in many of the products we have been investing in, tightly managed our expenses, and again saw loan growth in both our consumer and institutional businesses.”

Citi reported a 3% year-over-year increase in global consumer banking revenue. In North America, retail banking revenue rose 12%, excluding mortgages. Citi cited "continued growth in loans and assets under management," as well as higher interest rates.

The bank's international consumer business saw an 8% revenue increase, driven by higher loans and deposit volumes growth.

Citi's end-of-period loans, meanwhile, rose 2% to $653 billion, while deposits increased by 3% to $964 billion.

Shares of Citigroup have risen 26% this year, easily outperforming the broader market. The S&P 500 has gained 14% in 2017.

Citigroup's stock has also outperformed those of other big banks. Shares of JPMorgan Chase and Bank of America are up 11.9% and 16.9%,, respectively.

Folks who follow macroeconomic developments are also aware that Citigroup could benefit from tighter monetary policy in the near future. The U.S. Federal Reserve signaled a December rate hike in the summary of its Sept. 20 meeting.
Shares in C opened Thursday took on 31 cents to $75.25. ]]>
<![CDATA[Enterprise Group’s Hart Oilfield Rentals: Custom, Cost-Effective Infrastructure]]>Thu, 12 Oct 2017 09:51:46 ESThttp://www.baystreet.ca/articles.aspx?id=38459


Simply, if you are building a mining or oil business Hart rents customized equipment for project sites, drilling & completions and facilities that require mobile infrastructure.

It makes zero sense to expend valuable capital to purchase generators, offices, WC’s etc. As well, each project is different so flexibility, customization and ease of transport is key.



“Our large competitive advantage is the ability to what we refer to as ‘combo technology,” states Joel Bardwell, Senior Manager at Hart. “Whether on a skid or one of our proprietary portable trailers, we can deliver not only the equipment required, but customize it to be the most cost effective. Customers appreciate the approach and with our ongoing R&D and patent/patent pending profile, both served us well during the downturn and positions us well for the rapidly increasing business, both from previous and new clients.”

Hart currently has 6 locations that are strategically located throughout west central and northern Alberta and northeastern British Columbia. These 6 locations have allowed Hart to establish 6 complimentary “service circles” that slightly overlap and allow Hart to deliver oilfield site set-up services and equipment rentals efficiently to its customers as well as respond quickly to requests for service or repairs to its equipment when required.

Early on, Hart realized that the uniqueness of its approach warranted patent filings for equipment as well as industrial designs. With approximately 25 equally divided between Canada and the US, the practice both cements Hart’s reputation as an innovator as well as protect the Company and Enterprise shareholders from interlopers.

There are always interlopers.



It should also be noted that Hart does not sell the custom equipment. Hart is constantly developing equipment to add to its robust and state of the art rental pool: And all with
safety the primary consideration.

Just as with all the Enterprise Group’s subsidiaries, attention to detail is a given. Reactive and proactive to customer needs is what cuts it out of what is already a small herd. Whether resource, municipal needs, pipelines or any other infrastructure pursuit, that word - infrastructure - should be reflected to a greater or lesser degree in every portfolio. US peers are hitting new highs and others, such as Enterprise’s share price is being wrongly assaulted by a volatile oil price.

The bottom line is that over the years Enterprise has made savvy, money making purchases and sales. TC Backhoe sold in 2016 for approximately C$20 million. The Company was purchased in 2007 for C$12 million and under the Enterprise umbrella generated $150 million. The sale was done during the recent downturn, but had been planned previously and drastically lowered and improved the Company’s financials.

Having successfully steered through a blistering downturn, which seems to have unfairly punish a stock that has a breakup of C$0.85 but is trading at C$0.30, it seems a good addition to a junior portfolio.

Investors will also note that as the Company is traded on the TSX that adds to a list of bonafides to Enterprise that investors would be wise to take stock.



Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated ten thousand dollars for its efforts in distributing the TSX:E profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[WADA Lifts CBD Ban for Professional Athletes and their Doctors]]>Thu, 12 Oct 2017 08:02:09 ESThttp://www.baystreet.ca/articles.aspx?id=38458
The World Anti-Doping Agency (WADA) just removed hemp-derived cannabidiol (CBD) from its 2018 List of Prohibited Substances, freeing up athletes in the largest international athletic associations in the world like the IOC and FIFA as well as major sports leagues like UFC, NCAA, NFL, NBA, NHL, MLB, and many more to use CBD-infused products as to treat pain and inflammation based disorders.

As WADA is a global governing body, now athletes around the world can use CBD to treat pain, inflammation and injuries, without the risk of league suspension or a loss of sponsors. Professional athletes around the world can now use Phivida’s CBD infused functional foods and natural health brands, free from WADA restrictions, for the first time in the history of competitive sports.

Cannabinoids have just got mainstream, starting with the major leagues. But it’s investors, and CBD-infused infused functional foods and natural health products brands that stand to benefit the most.

According to Allied Research, the global anti-Inflammatory therapeutics market is projected to top $106 Billion USD by 2020, dominated by OTC drugs like Ibuprofen ($14.2 billion USD by 2022). The US opiate drug as an additional $17.7 billion USD by 2021 dominated by Oxycontin, Percocet and Vicodin. Both the NSAIDs and opiate markets are dominated by pain and inflammation pharmaceutical mogul Bayer (BAYN.DE), with a market capital of over $96 billion.

Cannabidiol is widely studied as a powerful anti-inflammatory and was even part of a US Department of Health patent application for anti-oxidant and neuroprotectant properties.

RISING DEMAND FOR CBD-INFUSED PRODUCTS

Timing the market is vital for maximizing investment returns. There is no better example of fortunate timing than WADA’s announcement coinciding with the launch of Phivida Holdings Inc.’s CBD-infused functional foods and natural health products, and the filing of prospectus for an initial public offering and an application to list its class A shares on the Canadian Securities Exchange (CSE).

As a premiere CBD brand, Phivida is perfectly positioned to capture a leadership market share in this emerging global natural health products market. The Phivida IPO offers investors with exposure to three major growth trends within a global health and wellness $1 Trillion USD in 2017.

Bloomberg predicts US cannabinoid products as a $50 billion USD market by 2020. Within the cannabinoids market, Phivida has created its own unique products category – functional CBD edibles.

High Times magazine produces a top ten edibles list and this year six of them were cannabinoid infused beverages. Phivida specializes in the CBD beverages avoiding a saturated confectionary soft drinks market with functional CBD iced teas, CBD protein shakes and CBD vitamin juices.

Health care practitioners, and now sports medicine professionals, and major nutraceutical distributors cite the paradigm shift from chemical based pharmaceuticals to phytonutraceuticals.

Supplements as a whole market is exploding, having gone from a $37 billion US estimate in 2015, to an expectation of $220 billion globally by 2022.

Nutrition Business Journal cites the two fastest growing categories as; meal replacements (14.8%) and sports nutrition (11.6%), two flagship CBD product lines at Phivida – both infused with a high dose of cannabidiol. Phivida’s nanoencapsulation technology loads CBD into a protective, hydrophilic, liposomal membrane that bonds better with cells. The result is a faster acting longer lasting absorption rates, with up to 400% more bioavailability and a timed release for enhanced duration in the bloodstream, and solubility.

Functional foods have surpassed traditional food topping a $100 billion USD back in 2015. The functional food industry is in the process of a massive consolidation as over $10 billion USD of new M&A deals were completed in 2016 alone.

Major food companies are acquiring new organic and functional food brands at a staggering rate, lead by multi-national conglomerates such as Hains Celestial (NASDAQ: HAIN), PepsiCo (NYSE:PEP) and General Mills (NYSE:GIS).

It’s no wonder that major retailers in both the grocery sector, and the nutritional supplements space are champing at the bit to grow their selection of products for consumers.

WADA’s prohibition lift may be the catalyst needed for supplement giant GNC Holdings Inc. (NYSE:GNC) to get its year back on track. Having fallen from over $20 to just over $8 within the year, the ability to introduce new lines of nutritional supplements with pain relieving qualities could be a shot in the arm for GNC.

Whereas major grocery and pharmacy chains, such as Canadian retail giant Loblaw Companies Inc. (TSX:L)(OTC:LBLCF), which owns the well-established Shoppers Drug Mart chain. Unlike GNC, which to-date has been reluctant to carry CBD products in-store, Shoppers Drug Mart has been very open about its willingness to carry CBD and marijuana-related products on its shelves.

It’s still to be determined when and if that same level of acceptance will be seen on the US side of the border. GNC currently doesn’t carry any CBD-infused products, selling only hemp proteins as a remotely close cousin. Nor is CVS Health Corporation (NYSE:CVS), yet.

Online mega-retailer Amazon.com Inc. (NASDAQ:AMZN) is already selling CBD products. On track to hit the very first $1 trillion valuation, Amazon is ahead of the curve on the blossoming CBD sector.

Whole Foods CEO John Mackey stated he would support cannabinoid products sold in Wholefoods “if only the plant was legal to use and the local community approved.”

Not only is CBD-Hemp Oil extract legal under the Farm Bill, but WADA’s new rules has the potential for a massive demand from professional athletes, sports medicine practitioners and alternative health care practitioners and the everyday active health conscious consumer. It looks like John might get his wish.

Plant-based supplements like CBD are no longer limited to the estimated 17,500 licensed alternative health care practitioners, as majority of supplements are now sold through big box FCMD (food, club, mass and drug) retail locations.

Walgreens, CVS and Walmart combined for a total of 27,087 on-site pharmacists at 15,208 stores across the United States. With Amazon’s acquisition of Wholefoods earlier this year, it’s clear that the majors are looking to capitalize on the health-conscious consumer.

Now it’s a matter of CBD’s true market infiltration to take hold, and for producers to begin stocking only the best CBD infused FFNHP formulations.

Primed and ready to supply these retailers with timely product, Phivida boasts an entire line of CBD functional foods and natural health products, doctor formulated for enhanced athletic performance and everyday preventative health for active families.

INDUSTRY AND ORGANIC ADVANTAGE

Totally legal, and boasting a laundry list of health benefits, cannabidiol (CBD) is making waves through the food and beverage industry in the form of several new products.

So it’s no wonder that any new producer of CBD products will want to seek out the expertise of those already familiar with the food and beverage industry.

Assembling an impressive array of talent, Phivida’s management team is built to master not only its formulation, but also its branding and retail distribution.

Among the names on the company’s deck are Directors Bill Ciprick and James Bailey, who each come with decades of branding and distribution experience for industry heavy-hitters, such as Proctor and Gamble Health Care, and Red Bull Canada.

But for the consumer, the most important aspect to consider beyond retail availability is that of the product’s organic, whole-plant blends and formulations.

Phivida infuses full-spectrum CBD Hemp Oil extracts into special blends of functional foods and natural health products (FFNHP). All nanoencapsulated CBD used in Phivida’s products is hemp-derived from licensed hemp farms and federally legal and eligible for sale in any retail channel.

The company’s CBD-infused functional beverages are nanoencapsulated for enhanced bioavailability, and doctor-formulated for targeted outcomes. Phivida boasts quality-, and safety-tested products that are cGMP manufactured to the highest quality assurance standards.

Phivida CBD Vitamin Drinks use certified organic and plant-based ingredients. Phivida’s CBD infusions are also vegan, gluten- and soy-free with no sugar added and contain at least 35% RDA of Vitamin B complex and Vitamin C.

Other key sports performance ingredients include premium electrolyte replacements, glutamine for muscle, bone and joint repair, resveratrol for added anti-oxidants, blended in an all-natural fruit and vegetable puree with no artificial colours or flavours added.

Former President of the BC College of Naturopaths, Dr. Brian Martin, states; “Phivida offers legal, clinical grade, CBD, third-party tested, and safe for practitioners to recommend to athletes and patients.” Marijuana is federally illegal in the United States, but hemp provides a legal option for clinicians. WADA’s new ruling now opens CBD to team physicians, physiotherapists, nutritionists and kinesiologists. “Phivida is a high-quality brand for athletes who need healthier, non-addictive treatments for pain and inflammation,” said Dr. Martin.

WADA’s now-positive stance on CBD represents a great opportunity for Phivida. Competitive athletes in high-impact sports like football, hockey and mixed martial arts are often plagued with a lifetime of debilitating physical injuries and mental health conditions.

Phivida’s CBD infusions give athletes, their trainers, and medical staff a whole-plant nutraceutical alternative to highly addictive opiate pharmaceuticals to treat chronic pain and inflammation from these injuries and afflictions.

ATHLETIC ENDORSEMENT

Earlier this year, the New York Times published a neuropathology study that found that 99% of former NFL players tested positive for Chronic Traumatic Encephalopathy (CTE). The NFL supports the NFL Players Association’s (NFLPA) study on the use of cannabinoids to treat chronic pain inflammation based disorders, like CTE, according to a Sports Illustrated article published on August 1st, 2017.

The NFLPA was coincided by the launch of the Your Mind Your Body Campaign designed to equip current and former players with the tools needed to achieve a healthy lifestyle, both physically and mentally and encourages an open dialogue on pressing health and safety issues, including CTE, and mental health.

Use of cannabinoid-based alternatives to opiates is not a new issue for the NFL. Many former players have become advocates for CBD as alternatives to narcotics, including former Baltimore Raven Eugene Monroe, Denver Bronco Jake Plummer, Chicago Bear Jim McMahon, and Ricky Williams who publicly stated a belief that “60-70% of all NFL athletes use medicinal marijuana”.

Despite the fact that both the NFLPA and NFL endorse a study of marijuana as a potential pain-management tool, the NFL currently suspends players who test positive for the drug and modified the threshold for a positive test for marijuana (i.e. THC). Finally, WADA’s new adoption of CBD as an approved substance, gives the NFL and its players hope for immediate relief, without controversy.

Phivida’s CBD-infused functional foods and natural health products are formulated with a special blend of nutraceuticals for enhanced athletic performance, and infused with a therapeutic dose of nanoencapsulated cannabidiol from hemp.

"This pain is never going away. My body is damaged," Eugene Monroe, 30, stated in a Washington Post article. "I have to manage it somehow. Managing it with pills was slowly killing me.”

With the lift on the CBD ban, WADA is finally taking sensible action on behalf of the athletes it is tasked to protect.

“Cannabidiol is no longer prohibited,” WADA said, maintaining that THC will remain as a banned substance. WADA cited the reason for the removal of cannabidiol from the banned list was because “it is not a cannabimimetic and does not mimic the effects of THC.”

WADA further clarified: “THC is still a prohibited substance.”

THC or tetrahydrocannabinol is the psychotropic chemical compound in marijuana that contributes to euphoric effects. Many CBD products on the market are marijuana derived and contain THC.

Purity levels in CBD-infused products will give an industry advantage to those producers that can utilize the most CBD, without delivering any THC.

Phivida’s nanoencapsulated CBD-Hemp Oil extracts, edibles and infusions, are federally legal, derived from Farm-Bill-compliant farms, and are now 100% WADA-compliant sources for cannabidiol. As well, they’re coming to a store near you.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated eight hundred dollars for its efforts in distributing the Phivida article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
]]>
<![CDATA[Valeant (VRX) Cleans Up its Debt]]>Thu, 12 Oct 2017 07:40:19 ESThttp://www.baystreet.ca/articles.aspx?id=38457
Valeant, on October 3, issued a $1-billion debt offering that lower the total upcoming maturities.

Valeant priced its $1-billion principal amount of 5.5% senior notes due in 2025. It will use the proceeds to roll over existing debt. The issuance is not trivial: the lower interest will save the company money while simultaneously pushing out the maturity date.

The low interest rate offered suggests the market has a healthy appetite for Valeant’s debt, so the fear of any bankruptcy is now off the table. Valeant now has around $26 billion in debt and $24 billion net of cash. In June, the company’s net debt was $26.7 billion. The sale of Dendreon raised $811 million, while iNova brought in $923 million. The net effect is that Valeant will have $3.9 billion maturing in 2020.

Assuming Valeant generates $1 billion in free cash flow, the company’s interest on debt in 2020 are covered. It sets the stage for refinancing for the debt due in 2021 and beyond.
]]>
<![CDATA[Athersys Hikes on MultiStem Hookup with Japanese Firm ]]>Wed, 11 Oct 2017 12:24:52 ESThttp://www.baystreet.ca/articles.aspx?id=38456Based on the agreement, Athersys and NCLi will engage in technology transfer activities at NCLi’s facility in Japan, and NCLi will begin contract manufacturing support for commercial development of the product in Japan. Athersys’ collaborator, HEALIOS K.K. (Healios), has an exclusive license to develop and market MultiStem in Japan for ischemic stroke, and is currently conducting its registrational clinical study, TREASURE, in Japan.

A news release issued Wednesday claimed therapeutic treatment with MultiStem may extend the stroke treatment window to 36 hours from the current three to four-and-a-half hours with existing standard of care, which would enable many more stroke patients to receive treatment than under the current standard of care and may also meaningfully enhance patient recovery.
Currently, there are nearly 17 million people that suffer a stroke globally and, on average, someone in the United States has a stroke every 40 seconds.
Athersys shares gained 11 cents, or 4.9%, midday Wednesday to $2.34, within a 52-week trading range of $1.02 to $2.63.
]]>
<![CDATA[Delta Gains Altitude on Q3 Earnings]]>Wed, 11 Oct 2017 11:12:22 ESThttp://www.baystreet.ca/articles.aspx?id=38455The number-two U.S. airline reported adjusted earnings per share of $1.57, beating analysts' expectations of $1.53 a share for a quarter that ended with hurricanes that crippled operations.

Earnings per share were about 8% lower over the year-earlier period.

The airline posted quarterly revenue of $11.06 billion, slightly higher than expectations for $11.03 billion in the three months ended in September.

Delta's passenger revenue per available seat mile — a key income metric — rose 1.9%, in line with the airline's updated forecast earlier last month. It said it expects a 2% to 4% increase in passenger unit revenue in the fourth quarter, but warned that higher fuel costs would likely crimp operating margins for the last three months of the year.

Delta posted higher revenue in domestic and Latin American and trans-Atlantic operations, despite powerful storms in the Southern U.S. in August and September.

Delta executives will likely address the impact from deadly storms that hit carriers' hubs late this summer, as well as a bitter trade dispute between two Delta suppliers, Boeing and Canada's Bombardier.

Hurricane Irma, which struck Florida and Delta's hub in Atlanta, forced the airline to cancel more than 2,000 flights.

Delta shares began Wednesday’s trading up 37 cents to $53.07
]]>
<![CDATA[BlackRock Rocks Markets on Q3 Figures ]]>Wed, 11 Oct 2017 10:42:55 ESThttp://www.baystreet.ca/articles.aspx?id=38454Total assets under management rose 17% to nearly $6 trillion as net inflows easily beat Wall Street expectations.

Here's how the company's results compare to Wall Street's expectations: EPS came in at $5.92 per share, compared with $5.56 expected. Revenue was $3.233 billion versus $3.096 billion expected.

Total assets under management registered at $5.977 trillion versus experts’ projected $5.94 trillion.
Net inflows were $96 billion versus $71.62 billion expected.
BlackRock also said its iShares exchange-traded funds business saw $52.3 billion in long-term net inflows, led by $33.1 billion in equity inflows. Assets under management for iShares totaled $1.640 trillion, accounting for 27% of BlackRock's total assets.

The company said cash assets rose 6 percent from a year earlier to $425.4 billion.

"One of the greatest problems we still have in the world is how much money is sitting on the sideline," according to CEO Larry Fink. "Even in places like Japan, there's $5 trillion in cash earning negative return. In Germany 72% of savings are in bank accounts. We're seeing some of that unlocked (and), we're seeing people put some of that money to work."

The company's stock has been on fire this year, advancing 21.5%. By comparison, the overall S&P 500 is up about 14% in the period. BlackRock shares have also outperformed the financials sector, which is up 13% in 2017.
BlackRock shares opened Wednesday up $2.80 to $468.29 ]]>
<![CDATA[Emblem Positioned to be Disruptive in the Medical Cannabis Industry]]>Wed, 11 Oct 2017 08:44:45 ESThttp://www.baystreet.ca/articles.aspx?id=38453
First, it has become apparent that for the foreseeable future, a few select Canadian marijuana companies will lead the sector growth, particularly over the US.


Second, the virtually unlimited growth in the space will and is being realized through the pharmaceutical developments, particularly in the pain, sleep and anxiety markets. Pain markets alone are $60 billion and will rise over 30% to $83 billion by 2024. Pain and sleep markets are two of the largest component markets.

Key to this growth at companies such as Emblem (TSXV:EMC) is when society embraces marijuana as what could well be the first line of defense and treatment for many afflictions, including the devastating opiate crisis.

“Emblem is focused on developing mainstream medical therapies to deliver consistent, 12-hour relief, with reduced side effects.,” states Gordon Fox, CEO Emblem Corp. “Canada is one of the few jurisdictions in the world –including the USA--with a path to regulatory approval of cannabinoid based medication. ACMPR has mechanisms for approval and these mechanisms are currently being expanded. The Canadian medical community can participate in research and clinical trials and share data and results across provincial boundaries.

With our recently announced exclusive arrangement with CanntabTherapeutics, Emblem is executing to plan.”

The Canntab Deal

Very simply, Canntab has the proprietary sustained release formulation: Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana.

Canada is one of the few jurisdictions in the world with a path to regulatory approval of cannabinoid based medication.

- The current medical cannabis market in Canada is about $400 million. It is searching for better dosage formats. Simple oils have grown to about 35% of the market in less than a year. More appropriate dosage formats are expected to have comparable effects in the market.

- Currently, Cannabis tends to require re-dosing. A titratable, sustained release formulation would have substantial appeal in the chronic neuropathic pain market. Anecdotally, that segment represents a reasonable percentage of the current$400 million medical cannabis market.

- The Canadian non-cannabis chronic pain pharmaceutical market is over $500 million and dominated by opioids and is expected to reach $42.16 billion worldwide by 2021. A cannabinoid based sustained release product has potential to enter that market.



From Emblem’s October 3rd Press Release:

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product. The Sustained Release Products will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

As per other Royalty Agreements in the Pharmaceutical Sector terms weren’t disclosed other than ‘double digit” royalty. To be clear this relationship with Canntab is extremely favorable to Emblem.

It cannot be overstated how important a develop this is for patients. Instead of waiting 5-10 years for a therapy to get to patients, cannabis based products take mere months. There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

The Global Opiate Crisis

While therapies will address particular conditions, anecdotally many patients know and have expressed the efficacy, ease of use and lack of side effects in pain management particularly.

Emblem plans to bring products to deal with neurological pain by fall 2018. Once the 12- hour delivery protocol is established, many afflictions can be addressed via the proper strain and titration.

Investors need to embrace the potential of this market and acquire some exposure. Choose carefully as there are many companies who have and will likely fail or price themselves out of the market.

Emblem’s business plan sets three divisions to be profit centres. From ongoing reasonable to maximum growth:

- Dried flower is the commodity space which provides superior, but generic product

- High quality strains (think aged single malt scotch versus JW Black) for the aficionado

- Top quality strains for ongoing therapeutics’ development.

Margins increase exponentially from dried flower to medical strains. Emblem (TSXV:EMC) is focused on the two markets above dried flower, although will be a major force in all three.

Marijuana Market Maturing Slightly. Invest Carefully, but Invest

The Marijuana space has matured somewhat from mining guys seeing a quick turn in fortunes by announcing some hair-brained participation to get their languishing stock prices up.

Then there the companies who conclude that more marijuana is better and are growing as much as they can.

Finally, there are a few companies, such as Emblem that have a solid growth plan and are not afraid to state their corporate intentions. Many comparisons are made to the UK’s GW Pharma as the direction a developing company should travel.

GW’s Sativex is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. GW’s ADS on NASDAQ in 2013 came at $8.90. Last trade at this writing was $114.07.

Fun Facts

- Some plant biologists got their early weed (60’s, 70’s) experience by serving time for possession, etc.

- Lots of anecdotal evidence that Big Pharma continues to pay doctors to keep their products at the forefront

The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

- AbbVie (NYSE:ABBV) : $4,104,000

- Novartis (NYSE:NVS) : $3,645,026

- Amgen (NASDAQ:AMGN) : $2,365,000

- Bristol-Myers Squibb (NYSE:BMY) : $1,388,187

- Gilead (NASDAQ: GILD) : $539,761



That alone should give Marijuana companies such as Emblem a place in your speculative portfolio.

Oh, yes. 10 percent of patients suffer from Trypanophobia. That fear keeps 20 percent of that number to never seek medical attention. Look it up…

Perhaps with the inevitable insertion of Marijuana based therapies should reduce or eliminate that number.

And how would Big Pharma ‘payola’ doctors for such a readily available and efficacious therapy? Bueller?

Next couple of decades should be interesting; with less pain, more sleep, relief from chronic disease as well as lives saved.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated four thousand dollars for its efforts in distributing the TSXV:EMC profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[AnaptysBio Makes Waves on Trial Data ]]>Tue, 10 Oct 2017 03:25:01 ESThttp://www.baystreet.ca/articles.aspx?id=38452Said CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.

“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.

AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.

Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
]]>
<![CDATA[Wal-Mart Hikes on Share Buyback Program]]>Tue, 10 Oct 2017 11:30:29 ESThttp://www.baystreet.ca/articles.aspx?id=38451Wal-Mart also unveiled a $20-billion share repurchase program to replace its existing plan. The company says the new authorization will be used over a two-year period.

The big-box retailer explained it will continue to focus on remodeling existing stores and incorporating "digital experiences" in place of building new locations.

Ahead of its annual investor day in Bentonville, Arkansas, Wal-Mart said it expects its U.S. e-commerce business to grow sales by roughly 40% in fiscal 2019. Online transactions surged 60% during the second quarter of this year, the retailer declared in August.

The company still expects adjusted earnings per share for the fiscal year 2018 to fall between $4.30 and $4.40.

For fiscal 2019, Wal-Mart said it expects earnings to increase about 5% year over year. Net sales for fiscal 2019 are expected to grow close to 3%, driven by same-store and e-commerce sales growth, the company added.

In fiscal 2019, across the U.S., Walmart will open fewer than 15 Supercenters and fewer than 10 of its Neighborhood Markets.

For fiscal years 2018 and 2019 combined, Wal-Mart is calling for capital expenditures to be about $11 billion, with e-commerce investments going toward enhancing the retailer's supply chain. Wal-Mart's international business will also invest more in fulfillment capabilities.

Shares in Wal-Mart galloped $3.53, or 4.4%, to $84.06
]]>